Comparative Pharmacology
Head-to-head clinical analysis: ANZEMET versus ZOFRAN ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZEMET versus ZOFRAN ODT.
ANZEMET vs ZOFRAN ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emesis.
Selective antagonist of serotonin 5-HT3 receptors, blocking serotonin binding in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
100 mg orally once daily, or 1.8 mg/kg (maximum 100 mg) intravenously over 15 minutes once daily.
8 mg orally disintegrating tablet (ODT) 30 minutes before chemotherapy; for prevention of nausea/vomiting, 8 mg orally twice daily.
None Documented
None Documented
The terminal elimination half-life is approximately 5-7 hours in normal adults, but may be prolonged in patients with hepatic impairment (up to 11 hours) or severe renal impairment.
Terminal elimination half-life approximately 3–6 hours in adults; prolonged to 8–15 hours in patients with severe hepatic impairment (Child-Pugh C) due to reduced clearance.
Approximately 70% of the dose is excreted in urine (mostly as metabolites, with less than 10% as unchanged drug) and about 20% in feces via biliary elimination.
Renal (47% as unchanged drug and metabolites, primarily glucuronide conjugates) and hepatic metabolism; about 25% excreted in feces; less than 10% excreted unchanged in urine.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)